BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
⚡ Executive Takeaway
Eli Lilly escalates its war on compounding with a stark public safety warning: tirzepatide mixed with vitamin B12 produces an uncharacterized impurity found in all 10 samples tested. Meanwhile, Ultragenyx's OTC gene therapy DTX301 hit its Phase 3 ammonia endpoint, Novo Holdings revealed a massive 34% asset collapse tied directly to its namesake drugmaker, and Pfizer confirmed the quiet wind-down of its Ignite biotech incubator. 👉 Read Full Analysis
🔮 What To Watch
Compounding Crackdown Accelerates: Lilly's B12 impurity data hands the FDA a definitive enforcement rationale. Watch for compounders to rapidly pivot away from B12 formulations—but Lilly proactively flagged glycine, pyridoxine, niacinamide, and carnitine as equally untested. The "personalization" legal defense is shrinking fast.
OTC Gene Therapy Timeline: Ultragenyx hit the first of two co-primary endpoints at 36 weeks; the second (treatment burden reduction) reads out at 64 weeks in H1 2027. A BLA decision likely extends into late 2027. RARE shares fell ~3% despite positive data, signaling investors remain cautious after recent pipeline setbacks.
Novo Nordisk Overhang: Novo Holdings' 34% asset decline mirrors NVO's 34% share drop in 2025—plus another 24% YTD. Watch the March 26 Novo Nordisk AGM for any strategic signals as the GLP-1 leader recalibrates against Lilly's market dominance.
🚀 Today's Top Story
Eli Lilly Warns of "Concerning" Impurity in Compounded Tirzepatide-B12 Products
What Happened: Eli Lilly issued a public safety warning Thursday flagging "significant levels of an impurity" in compounded tirzepatide products mixed with vitamin B12. The impurity was identified in all 10 samples tested from compounding pharmacies, telehealth platforms, and medspas.
The Science: Lilly's analysis found that a chemical reaction between tirzepatide and B12 (whether methylcobalamin, hydroxocobalamin, or cyanocobalamin) produces a novel impurity with unknown clinical effects. The company noted "nothing is known about its short- or long-term effects in humans," including its impact on GLP-1/GIP receptor interaction, toxicity, or immunogenicity.
The Context: Lilly also reported finding bacterial contamination and elevated endotoxin levels in compounded samples. The company has notified the FDA and is formally calling for a nationwide recall of all tirzepatide products combined with B12 or other untested additives.
Executive Impact: This dramatically intensifies regulatory and legal pressure on the compounding ecosystem. Compounders previously argued B12 additions constituted legitimate "personalization"; Lilly's data reframes the practice as the reckless introduction of novel, untested chemical entities.
🧬 Clinical & Research Updates
Ultragenyx DTX301 Hits Phase 3 Ammonia Endpoint in OTC Deficiency
The Data: The Phase 3 Enh3ance study met its first co-primary endpoint at 36 weeks: DTX301-treated patients showed an 18% reduction in 24-hour plasma ammonia compared to placebo (p=0.018) while maintaining average ammonia in the normal range.
Functional Benefits: Eight of nine patients with abnormal baseline ammonia reached normal levels rapidly. Treated patients reduced ammonia scavenger medications by 27% on average and increased protein intake ~13%—yet still maintained ammonia control. At Week 24, 71% of treated patients reported being "much improved" vs. 0% on placebo.
Safety: One treatment-related serious adverse event (acute hepatitis) resolved with steroid treatment. Hyperammonemic crises requiring hospitalization occurred in 5 placebo patients (including 1 death) versus 1 in the treatment arm (no deaths).
What's Next: The second co-primary endpoint (treatment burden reduction) is expected in H1 2027.
Capricor Releases Late-Breaking HOPE-3 Cardiac Data at MDA 2026
The Update: Capricor Therapeutics (CAPR) presented additional analyses from its pivotal Phase 3 HOPE-3 trial of deramiocel in Duchenne muscular dystrophy.
The Data: Showed LVEF improvement (+3.3 percentage points vs. placebo; p=0.017), fibrosis reduction (three-segment treatment difference in late gadolinium enhancement at 12 months; p=0.022), and an 83% slowing of disease progression on the Duchenne Video Assessment eat-10 task.
Catalyst: PDUFA is set for August 22, 2026. The asset is Priority Review Voucher eligible.
🏢 Corporate & Business Developments
Novo Holdings Reports 34% Asset Decline Tied to Novo Nordisk Collapse
The Financials: Novo Holdings released its 2025 annual results showing total assets under management fell to DKK 694 billion (€93 billion)—down 34% from DKK 1.06 trillion (€142 billion) in 2024.
The Driver: CEO Kasim Kutay attributed the stark decline directly to "the significant drop in the market value of Novo Nordisk." NVO shares fell 34% in 2025 and have dropped another 24% YTD to ~$39.
Investment Outlook: Kutay signaled deep caution, noting Novo Holdings is investing "billions less" in new life science companies due to geopolitical uncertainty and tech disruptions. However, the investment portfolio (excluding the Novo Nordisk stake) still grew from DKK 216B to DKK 226B.
Pfizer Confirms Ignite Incubator Wind-Down
What Happened: Pfizer disclosed in its annual report that it is shutting down Pfizer Ignite, the biotech incubator unit launched in 2022 to provide R&D services and equity partnerships to early-stage companies.
The Numbers: Ignite revenue fell 50% to $41M in 2025—less than 0.1% of Pfizer's $62.5B total.
The Signal: The closure marks Pfizer's strategic retreat from early-stage incubation toward late-stage asset discipline, a stark contrast to Lilly and Roche, which are actively bolstering their early-stage biotech investments.
Aveanna Healthcare to Acquire Family First Homecare for $175.5M
The Deal: Aveanna Healthcare (AVAH) will acquire Family First Holding LLC, a pediatric private duty nursing provider operating 27 locations across 7 states, for $175.5M in cash. Expected to close in Q2 2026.
KORU Medical Announces CEO Succession
Transition: CEO Linda Tharby will retire effective June 30, 2026. Chief Commercial Officer Adam Kalbermatten will become President on March 15 and CEO on July 1. Under Tharby's tenure, KORU achieved profitability and raised 2026 revenue guidance to $47.5M–$50M (+15-22%).
📅 Week Ahead Calendar
March 16-19: NVIDIA GTC 2026 (San Jose) — Watch for AI/compute implications for drug discovery and protein folding.
March 17: Glucotrack at LSI USA '26 (Dana Point) — 3-year implantable CBGM commercialization strategy.
March 18-19: ACIP Meeting — First meeting with Kennedy-aligned appointees Drs. Downing and Farella.
March 20: Rhythm Pharmaceuticals — Imcivree PDUFA (Acquired hypothalamic obesity; ~10,000 U.S. patients).
March 24: GSK — Linerixibat PDUFA (Cholestatic pruritus in PBC).
March 26: Novo Nordisk — Annual General Meeting.
March 28: Rocket Pharma — Kresladi PDUFA (LAD-I gene therapy).
🔒 BioMed Nexus Pro — Institutional Intelligence Brief
In Today's Pro Brief:
🧠 GLP-1 Compounding Endgame: Why Lilly's impurity data shifts the debate from economics to safety science.
⚖️ Ultragenyx (RARE) Risk Framing: We model the commercial path for DTX301 against lingering pipeline sentiment fatigue.
🧮 Market Signals: Tracking the 40% surge in Hims & Hers against the compounding crackdown.
📊 Week Ahead Calendar: GTC 2026, ACIP, and upcoming PDUFAs.
Selective 2026 sponsorship placements are available
Reply directly to discuss a partnership or submit an inquiry here